Extended Data Fig. 1: Participant disposition: a) CONSORT diagram; b) Individual treatment exposure and follow-up timeline.
From: Oral splicing modulator branaplam in Huntington’s disease: a phase 2 randomized controlled trial
*One participant from the placebo arm discontinued early but still completed week 33; 2 of the 8 participants from the branaplam 56 mg weekly arm who discontinued early still completed week 69. n, number of participants in each category; N, number of participants in the safety analysis set.
